Form 8-K

8-K — Silo Pharma, Inc.

Accession: 0001213900-26-109457

Filed: 2026-10-14

Period: 2026-10-13

CIK: 0001514183

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Unregistered Sales of Equity Securities

Item: Financial Statements and Exhibits

Documents

8-K — ea0308562-8k_silo.htm (Primary)

EX-10.1 — ASSET PURCHASE AGREEMENT, DATED OCTOBER 13, 2026, BETWEEN THE COMPANY AND LARRY KING (ea030856201ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0308562-8k_silo.htm · Sequence: 1

false

0001514183

2026-10-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported): October

13, 2026

Silo Pharma, Inc.

(Exact name of registrant as specified in its charter)

Nevada

001-41512

27-3046338

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

677 N. Washington Boulevard

Sarasota, FL

34236

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area

code: (718) 400-9031

N/A

(Former name or former address, if changed since last

report)

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the

Act:

Title of each class

Trading Symbol(s)

Name of exchange on which registered

Common Stock, par value $0.0001 per share

SILO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an

emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark

if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On October 13, 2026, Silo

Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Larry King (the “Seller”).

Pursuant to the Agreement, the Seller agreed to sell, and the Company agreed to purchase, certain software and related intellectual property

(the “Purchased Assets”).

In consideration for the

Purchased Assets, the Company issued to the Seller, 150,000 shares of its common stock, par value $0.0001 per share (the “Shares”).

The Shares are subject to a lock-up period beginning on the effective date of the Agreement and ending on the earlier of (i) twelve (12)

months after such date, (ii) a Change in Control, as defined in the Agreement, or (iii) written consent of the Company (the “Lock

Up Period”). During the Lock Up Period, the Seller may not, without the Company’s prior written consent, directly or indirectly,

offer, sell, contract to sell, hedge, pledge, grant any option, right or warrant to purchase, or otherwise transfer or dispose of any

of the Shares, or enter into any swap or other agreement or transaction that transfers, in whole or in part, directly or indirectly, the

economic consequence of ownership of any of the Shares.

The Agreement contains certain

representations, warranties and covenants of the parties that are customary for agreements of its type. In addition, the Seller agreed

to indemnify the Company for any misrepresentation or breach under the Agreement, infringement of any third-party right by any portion

of the software and any acts of gross negligence, fraud or intentional misconduct by the Seller.

The foregoing summary does

not purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which is filed as Exhibit 10.1 to

this Current Report on Form 8-K and incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth under Item 1.01 is incorporated

herein by reference.

The offer and sale to the Seller of the Shares was

made in reliance upon Section 4(a)(2) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

Item 9.01 Financial Statements

and Exhibits.

(d) Exhibits.

Exhibit No.

Description

10.1*

Asset Purchase Agreement, dated October 13, 2026, between the Company and Larry King.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange Commission upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange

Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SILO PHARMA, INC.

Date: October 14, 2026

By:

/s/ Eric Weisblum

Eric Weisblum

Chief Executive Officer

EX-10.1 — ASSET PURCHASE AGREEMENT, DATED OCTOBER 13, 2026, BETWEEN THE COMPANY AND LARRY KING

EX-10.1

Filename: ea030856201ex10-1.htm · Sequence: 2

Exhibit 10.1

ASSET PURCHASE AGREEMENT

THIS ASSET PURCHASE AGREEMENT (this

“Agreement”) is made between Larry King, (“Larry King”) (the “Assignor”),

and SILO PHARMA. INC., a Nevada corporation (“Assignee”), and is effective as of the date of the last signature

below (the “Effective Date”).

WHEREAS, Assignor has developed

the Software identified more fully on Exhibit A;

WHEREAS, Assignor

has agreed to sell and convey to Assignee, and Assignee has agreed to purchase the Software and the Assigned Intellectual Property (collectively,

the “Assigned Assets”) all as identified more fully on Exhibit A, on the terms and conditions set forth below.

NOW THEREFORE, in consideration of

these premises and the Parties’ respective covenants and obligations set forth below, the Parties agree as follows:

1. Definitions.

a. “Assigned Intellectual Property” means

the Intellectual Property Listed on Exhibit A.

b. “Confidential Information” means the Software

and all related data, documentation, materials and know-how.

c. “Intellectual Property” means any

and all: (a) technology, formulae, algorithms, procedures, processes, methods, techniques, knowhow, ideas, concepts, creations, inventions,

discoveries, and improvements (whether patentable or unpatentable and whether or not reduced to practice); (b) software, websites, content,

images, graphics, text, photographs, artwork, audiovisual works, sound recordings, graphs, drawings, reports, analyses, writings, and

other works of authorship and copyrightable subject matter (“Works of Authorship”);

(d) trademarks, service marks, logos and design marks, trade dress, trade names, fictitious and other business names, and brand names,

together with all goodwill associated with any of the foregoing (“Trademarks”);

(e) domain names, uniform resource locators and other names and locators associated with the Internet (“Domain

Names”); (f) information and materials not generally known to the public, including trade secrets and other confidential

and proprietary information (“Trade Secrets”); (g) tangible embodiments

of any of the foregoing, in any form or media whether or not specifically listed herein; and (h) all Intellectual Property Rights associated

with the foregoing.

d. “Intellectual Property Rights” means any

and all rights (anywhere in the world, whether statutory, common law or otherwise) relating to, arising from, or associated with Intellectual

Property, including: (a) patents and patent applications, utility models and applications for utility models, inventor’s certificates

and applications for inventor’s certificates, and invention disclosure statements (“Patents”);

(b) copyrights, Mask Work rights and all similar or equivalent rights with respect to Works of Authorship and all registrations thereof

and applications therefor (including moral and economic rights, however denominated) (“Copyrights”);

(c) other rights with respect to Assigned Assets, including registrations thereof and applications therefor; (d) industrial design rights

and registrations thereof and applications therefor; (e) rights with respect to Trademarks, and all registrations thereof and applications

therefor; (f) rights with respect to Domain Names, including registrations thereof and applications therefor; (g) rights with respect

to Trade Secrets, including rights to limit the use or disclosure thereof by any Person; (h) rights with respect to Databases, including

registrations thereof and applications therefor; and (i) any rights equivalent or similar to any of the foregoing.

e. “Object Code” means the fully compiled

version of the Software that can be executed by a computer and used by an end user without further compilation.

f. “Open Source Software” means any software

component that is distributed as “free software,” “open source software,” or pursuant to any open source copyright

license agreement, including the GNU General Public License, GNU Library or Lesser Public License, GNU Affero General Public License,

MIT License, Apache License, Artistic License and BSD Licenses, or any other obligation, restriction or license agreement that substantially

conforms to the Open Source Definition (opensource.org/osd) as prescribed by the Open Source Initiative or otherwise controls the distribution

and use of one or more software components or that may require disclosure or licensing to any third party of any source code with which

such software component is used or compiled.

g. “Purchase Price” means one hundred fifty

thousand (150,000) shares of common stock, par value $0.0001 per share, of the Assignee.

h. “Software” means that certain software

comprising the entirety of the source code and object code for all modules for the design, appearance, content, features and functionality

of the web- based tools currently marketed as “Reputation Endpoints,” together with all related data, materials, know-how,

algorithms, documentation, and all derivative works, updates, improvements, modifications and enhancements made by or on behalf of any

Assignor as further described on Exhibit A, but excluding those portions of Open Source Software identified on Exhibit

i. “Source Code” means the human-readable

version of the Software that can be compiled into Object Code.

2. Sale and Assignment.

In consideration of the Purchase Price, Assignor irrevocably sells, assigns, grants, conveys and transfers to Assignee and its successors

and assigns, without any reservation whatsoever and without further consideration, and Assignee hereby accepts, all right, title and interest

throughout the world, free and clear of any licenses, liens or encumbrances, in and to the Assigned Assets, including all of the Software

and all Intellectual Property associated therewith, that Assignor may now have or later acquire (the “Assets”). For any Trademarks,

Assignor hereby assigns all good will associated therewith. Without limiting the forgoing, Assignor assigns: (i) all rights to register

and Intellectual Property, commercialize, exploit, reproduce, copy, distribute, publicly perform and display, synchronize, prepare derivative

works from, adapt, license and assign), and all other intellectual property rights, proprietary rights and legal protections; (ii) registrations,

renewals, extensions, reversions and restorations of any such rights; (iii) income, royalties, damages and payments, now or later due

or payable, with respect to any such rights; and (iv) claims and causes of action, in law or in equity, for past, present or future infringement

or misappropriation

3. Purchase

Price. Within five business days of the Effective Date, Assignee shall deliver to the Assignor a certificate (or book entry confirmation

of registration and issuance) evidencing the Purchase Price in full satisfaction of all amounts owed by Assignee in connection with this

Agreement.

4. Delivery. Within

three calendar days of receiving the Purchase Price, Assignor shall deliver to Assignee one digital copy of all Software (including Source

Code and Object Code, as applicable), as it exists as of the Effective Date, in a format that is (a) readable and usable by a programmer

of ordinary skill and contain all information, in human readable form, that such a programmer would need in order to understand, compile,

build, maintain, modify, correct and operate the Software, including any integrated Open Source Software, without undue experimentation,

difficulty or expense; (b) not password protected, encrypted or subject to other security measures that might impede Assignee’s

ability to access or use the Software; (c) accurately labeled; and (d) in media and formats that are fully operable in and compatible

with Assignee’s operating environment and technology systems.

Representations and Warranties. Assignor represents and warrants that the Software and all Intellectual Property associated therewith

(a) is an entirely original and independent creation; (b) contains no harmful or malicious code; (c) does not violate any law, rule or

regulation or infringe any third-party right; and (d) -- was not developed using, has not been distributed with, and does not contain

or operate in such a way that it is compiled with or linked to, any Open Source Software, except for the Open Source Software expressly

identified on Exhibit B, does not contain, link to, rely upon, or incorporate any Open Source Software, and is not subject to any “copyleft”

or open source license terms that would require the public disclosure, licensing, or distribution of any proprietary Source Code of the

Software. Assignor further represents and warrants that Assignor (e) is the exclusive author of the Software and the exclusive owner

of all Intellectual Property in and to the Software, free and clear of liens, security interests and other encumbrances; (f) is in actual

possession of and has exclusive control over a complete and correct copy of the Software; (g) has not caused or allowed any third party

to have a license to any Intellectual Property Rights in or to the Software; (h) has not registered or applied for registration of any

portion of the Software, or any Intellectual Property Rights in or to any portion of the Software, or any patent related to any portion

of the Software, in any jurisdiction; (i) has not done, and will not do, any act that encumbers the Software or that may threaten, impair

or prejudice Assignee’s rights in the Software; and (j) has full right, power and authority to execute this Agreement. Assignor

further represents that the Assets include all of the Software and Intellectual Property that are used to operate the business of the

Company, or necessary to enable the Company to conduct such business in the same manner as currently conducted. Assignee is induced by,

and relying upon, Assignor’s representations and warranties contained in this Agreement, and Assignee would not accept this Agreement

without them.

6. Lockup.

Each share of common stock of Assignee received by Assignor in connection with this Agreement shall be subject to a lock-up

beginning on the Effective Date and ending on the earlier of (i) the twelve (12) months after such date, (ii) a Change in Control,

as defined below, or (iii) written consent of Assignee, at Assignee’s sole discretion, provided Assignee’s consent shall

apply to all shares of Assignee common stock issued pursuant to the Agreement (the “Lockup

Period”). Assignee shall not without prior written consent, directly or indirectly, (i) offer, sell, offer to sell,

contract to sell, hedge, pledge, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,

right or warrant to purchase or sell (or announce any offer, sale, offer of sale, contract of sale, hedge, pledge, sale of any

option or contract to purchase, purchase of any option or contract of sale, grant of any option, right or warrant to purchase or

other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or

could be expected to, result in the disposition by any person at any time in the future), any Assignee common stock acquired

pursuant to this Agreement or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part,

directly or indirectly, the economic consequence of ownership of any Assignee common stock, whether or not any such swap or

transaction described in clause (i) or (ii) above is to be settled by delivery of any Assignee common stock.

7. Further Assurance.

Assignor shall cooperate fully and promptly with Assignee, and shall execute and deliver all such other documents, and shall take all

such further action as may be necessary or appropriate to perfect, secure and vest in Assignee ownership of and all Intellectual Property

Rights in and to the Assigned Assets .

8. Indemnity.

Assignor shall indemnify, defend and hold harmless Assignee and its parent, subsidiaries, directors, officers, employees, agents, successors

and assigns from and against all liability, losses, damages, costs and expenses (including reasonable legal fees) arising out of any demand,

claim, judgment, order or proceeding related to (a) any misrepresentation, or breach of warranty or this Agreement, by any of Assignor;

(b) infringement of any third-party right by any portion of the Assigned Assets; or (c) any acts of gross negligence, fraud or intentional

misconduct by any of Assignor. Notwithstanding anything to the contrary in this Agreement, Assignor’s total aggregate liability

arising out of or relating to this Agreement, whether in contract, tort (including negligence), or otherwise, shall not exceed the total

fair market value of the Purchase Price received by Assignor as of the Effective Date.

8.1 Survival. The representations

and warranties of the Parties contained in this Agreement shall survive the Effective Date for a period of twelve (12) months, after which

time all such representations and warranties shall expire and be of no further force or effect; provided, however, that any claim for

indemnification under Section 8 that is properly asserted in writing prior to such expiration date shall survive until finally resolved.

9. Confidentiality.

Assignor shall maintain the existence and terms of this Agreement in strict confidence and shall not disclose such terms to any third

party, except to legal counsel for the purpose of obtaining advice regarding this Agreement or otherwise as expressly required by law.

Assignor shall not use the Confidential Information and shall not disclose or allow disclosure of the Confidential Information without

Assignee’s prior express, written consent. Promptly upon Assignee’s request, Assignor shall deliver or destroy, as instructed,

all of the Confidential Information.

10. Entire Agreement;

Amendments. This Agreement contains the complete and final agreement between the Parties regarding the subject matter of this Agreement.

No amendment to this Agreement is valid unless made in writing and signed by all Parties to this Agreement.

11. No Waiver.

No failure or delay by either Party in enforcing an obligation or exercising a right or remedy will be deemed a waiver of that obligation,

right or remedy by that Party. No waiver by either Party of a right or remedy with respect to the other Party’s breach of a term

of this Agreement will be deemed a waiver of a right or remedy with respect to any other breach of any other term of this Agreement. No

waiver of a right with respect to a particular obligation in one circumstance will prevent a Party from subsequently requiring compliance

with that obligation on other occasions. The doctrine of affirmation by implied election will not apply.

12. Severability.

If any portion of this Agreement is found to be invalid or unenforceable by any court of competent jurisdiction, the Parties shall negotiate

in good faith to amend the invalid or unenforceable portion in accordance with the Parties’ mutual intent. If no agreement is reached

within five calendar days, the invalid or unenforceable portion, as identified as narrowly as possible, will be stricken from the Agreement,

and such action will not affect in any respect whatsoever the validity or enforceability of the remainder of the Agreement.

13. Governing

Law. This Agreement is governed by and will be construed in accordance with the laws of the State of Florida, without giving effect

to any choice of law or conflict of laws principles.

14. General.

This Agreement is binding upon and shall inure to the benefit of the Parties and their respective successors and assigns. This Agreement

is the result of arms-length, good faith negotiations and each Party had every opportunity to review the Agreement with its own counsel.

Any rule of construction that a contract is to be construed against the drafter will not apply. This Agreement may beexecuted in counterparts,

each of which will be deemed an original, but all of which together will be deemed one and the same agreement.

To evidence the Parties’ agreement, the Parties

have executed this Agreement below as of its Effective Date.

ASSIGNOR:

ASSIGNEE:

LARRY KING

SILO PHARMA, INC.

By:

(sign)

/s/ Larry King

(sign)

/s/Eric Weisblum

(print)

Larry King

(print)

Eric Weisblum

Its:

Chief Executive Officer

Date:

10/13/2026

Date:

10/13/2026

EXHIBIT A

[*]

EXHIBIT B

[*]

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Oct. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 13, 2026

Entity File Number

001-41512

Entity Registrant Name

Silo Pharma, Inc.

Entity Central Index Key

0001514183

Entity Tax Identification Number

27-3046338

Entity Incorporation, State or Country Code

Entity Address, Address Line One

677 N. Washington Boulevard

Entity Address, City or Town

Sarasota

Entity Address, State or Province

Entity Address, Postal Zip Code

34236

City Area Code

718

Local Phone Number

400-9031

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

SILO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration